Log in to your Inderes Free account to see all free content on this page.
Calliditas Therapeutics
5 following
ShowingAll content types
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
Redeye: Calliditas Update - The Final Countdown
Calliditas Therapeutics, Audiocast with teleconference, Q2'24
Calliditas Therapeutics: Calliditas Interim Report January to June 2024
Calliditas Therapeutics: Invitation to the presentation of Calliditas's interim report January - June 2024
Number of shares and votes in Calliditas Therapeutics
Calliditas Therapeutics: Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
Calliditas Therapeutics: Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Calliditas Therapeutics: Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics: Calliditas provides setanaxib patent update
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Calliditas Therapeutics: Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
Calliditas Therapeutics R&D Day, 2024
Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
Redeye: Calliditas Q1 - Powerful launch momentum
